Hexagon Capital Partners’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-7,839
| Closed | -$304K | – | 756 |
|
|
2025
Q1 | $304K | Buy |
7,839
+578
| +8% | +$22.4K | 0.06% | 155 |
|
|
2024
Q4 | $246K | Sell |
7,261
-2,308
| -24% | -$78.1K | 0.04% | 184 |
|
|
2024
Q3 | $391K | Sell |
9,569
-398
| -4% | -$16.3K | 0.08% | 120 |
|
|
2024
Q2 | $384K | Buy |
9,967
+791
| +9% | +$30.5K | 0.08% | 125 |
|
|
2024
Q1 | $393K | Buy |
9,176
+76
| +0.8% | +$3.26K | 0.09% | 119 |
|
|
2023
Q4 | $337K | Buy |
9,100
+4,067
| +81% | +$151K | 0.08% | 124 |
|
|
2023
Q3 | $182K | Buy |
5,033
+838
| +20% | +$30.4K | 0.05% | 181 |
|
|
2023
Q2 | $150K | Buy |
4,195
+1,329
| +46% | +$47.4K | 0.04% | 203 |
|
|
2023
Q1 | $102K | Sell |
2,866
-68
| -2% | -$2.42K | 0.03% | 238 |
|
|
2022
Q4 | $103K | Buy |
2,934
+253
| +9% | +$8.89K | 0.03% | 241 |
|
|
2022
Q3 | $79K | Buy |
2,681
+1,179
| +78% | +$34.7K | 0.02% | 280 |
|
|
2022
Q2 | $82K | Buy |
1,502
+1,010
| +205% | +$55.1K | 0.02% | 289 |
|
|
2022
Q1 | $27K | Sell |
492
-82
| -14% | -$4.5K | 0.01% | 455 |
|
|
2021
Q4 | $32K | Sell |
574
-112
| -16% | -$6.24K | 0.01% | 418 |
|
|
2021
Q3 | $33K | Hold |
686
| – | – | 0.01% | 395 |
|
|
2021
Q2 | $34K | Sell |
686
-1,224
| -64% | -$60.7K | 0.01% | 374 |
|
|
2021
Q1 | $85K | Sell |
1,910
-277
| -13% | -$12.3K | 0.02% | 250 |
|
|
2020
Q4 | $100K | Sell |
2,187
-58
| -3% | -$2.65K | 0.03% | 191 |
|
|
2020
Q3 | $96K | Buy |
+2,245
| New | +$96K | 0.03% | 181 |
|